TMPRSS2 for the diagnosis of prostate disease

Patent metadata

Field	Value
Publication number	US-9404159-B2
Application number	US-201314021363-A
Country	US
Kind code	B2
Filing date	Sep 9, 2013
Priority date	Dec 23, 2009
Publication date	Aug 2, 2016
Grant date	Aug 2, 2016

Abstract

Described herein are methods, compositions and kits directed to the detection the 5′ portion of TMPRSS2 mRNA for the detection and diagnosis of prostate disease including prostate cancer and benign prostatic hyperplasia.

First claim

What is claimed is:

1. A method for determining whether a TMPRSS2 RNA is present in an acellular body fluid, comprising:
(a) performing real-time reverse transcription polymerase chain reaction (RT PCR) on an acellular body fluid sample to amplify a polynucleotide from a 5′ region of TMPRSS2 RNA, if present, and a polynucleotide from a region of an endogenous control gene RNA present in the acellular body fluid, thereby generating a 5′ TMPRSS2 amplification product, if the TMPRSS2 RNA is present, and an amplification product generated from the endogenous control gene;
(b) determining the Ct value of the 5′ TMPRSS2 amplification product, if any, and the control gene amplification product;
(c) identifying the TMPRSS2 RNA as present if both the 5′ TMPRSS2 amplification product and the control gene amplification product have a Ct value of less than 40;
wherein amplification of the 5′ TMPRSS2 RNA is carried out with at least one primer pair comprising a forward primer and a reverse primer that bind to the 5′ region of TMPRSS2;
wherein the 5′ region of TMPRSS2 that is amplified is contained entirely within or overlaps with the 5′ untranslated region of the TMPRSS2 RNA; and
wherein the endogenous control gene is ABL.

2. The method of claim 1 , wherein the amplification of the 5′ TMPRSS2 RNA and the control gene RNA are performed in the same reaction vessel.

3. The method of claim 1 , wherein at least one of the primers in the at least one primer pair comprises a detectable label.

4. The method of claim 1 , wherein the 5′ TMPRSS2 amplification product, if any, is detected using an oligonucleotide probe comprising a detectable label.

5. The method of claim 1 , further comprising assessing the amount of prostate-specific antigen (PSA) in the acellular body fluid.

6. The method of claim 1 , wherein the acellular body fluid is serum or plasma.

7. The method of claim 1 , wherein two or more regions of the 5′ region of the TMPRSS2 RNA are amplified.

8. The method of claim 7 , wherein the amplification products of the two or more regions of the 5′ region of the TMPRSS2 RNA overlap.

Assignees

• Quest Diagnostics Invest Inc
• Quest Diagnostics Investements Incorporated

Inventors

• Sanders Heather R
• Albitar Maher

Classifications

• C12Q2600/16

  Primer sets for multiplex assays · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title